The interventional management of stroke (IMS) III trial (1) showed non-superiority of intra-arterial (IA) revascularization combined with intra venous (IV) tissue plasminogen activator (tPA) treatment over IV tPA alone, and the systemic thrombolysis for acute ischemic stroke (SYNTHESIS) trial demonstrated similar lack of favorable clinical outcomes for IA versus IV tPA therapy (2). This evidence concerns the gene PLAT and Stroke.